Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34,723,329
-
Total 13F shares
-
17,999,061
-
Share change
-
+820,618
-
Total reported value
-
$1,381,196,583
-
Put/Call ratio
-
343%
-
Price per share
-
$76.69
-
Number of holders
-
108
-
Value change
-
+$59,991,954
-
Number of buys
-
54
-
Number of sells
-
47
Institutional Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q1 2021
As of 31 Mar 2021,
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) was held by
108 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,999,061 shares.
The largest 10 holders included
Redmile Group, LLC, BAKER BROS. ADVISORS LP, PRICE T ROWE ASSOCIATES INC /MD/, Artal Group S.A., ALKEON CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP INC, BlackRock Inc., STATE STREET CORP, and Cormorant Asset Management, LP.
This page lists
108
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.